03A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol®) in Comparison With a Reference Standard
Aplisol@ PPD material
+ Reference Standard
+ Aplisol@ PPD material
Latent Infection+6
+ Actinomycetales Infections
+ Bacterial Infections and Mycoses
Diagnostic Study
Summary
Study start date: February 1, 2013
Actual date on which the first participant was enrolled.Primary: To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other mycobacteria. Secondary: To determine if the 2 investigational products have equivalent specificity for detecting subjects currently or previously infected with Mtb; To assess the tolerability of the investigational products in terms of the local and systemic reactogenicity events.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.152 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Males or nonpregnant females, age 18 to 70 years Negligible risk of manifesting a positive PPD test as evidenced by: Prior history of negative PPD test or interferon gamma release assay (IGRA) within 14 months before Screening No history of Bacillus Calmette- Guérin vaccination; or if vaccination status is uncertain, was born in the US and did not live outside the US as a child No history of Mtb or Mtb therapy (including isoniazid, rifampin, ethambutol, pyrazinamide, or streptomycin) No history of infection with atypical mycobacteria, including suspicious chest roentgenogram No history of high risk medical conditions (eg, HIV infection or other immunosuppressive conditions, severe chronic renal disease [as evidenced by a creatinine clearance < 30 ml/min], poorly controlled diabetes mellitus, silicosis, intravenous drug use, or alcohol abuse) No known close contact to a confirmed Mtb case (family or social setting) No history of living or travelling in India, China, Sub-Saharan Africa, or Southeast Asia in the past 6 months No exposure (other than casual) to high-risk environments for Mtb exposure (eg, prisons, homeless shelters); healthcare workers are allowed Exclusion Criteria: Subject is of childbearing potential and unable to use contraceptives; is planning pregnancy; is pregnant or lactating History of anaphylactic type reaction or other severe reaction to PPD in the past, including a history of blistering or sloughing Presence of conditions that may suppress TST reactivity, including: Protocol No. JHP-Aplisol-03 Confidential 04 May 2012 Page 8 of 38 Acute viral infections, including measles, mumps, chicken pox, human immunodeficiency virus (HIV1, HIV2). Mild viral syndromes are allowed. Acute bacterial infections including typhoid fever, brucellosis, typhus, leprosy, or pertussis Acute systemic fungal infection Live virus vaccinations within the past 6 weeks, including measles, mumps, polio, varicella, or FluMist® Metabolic derangements (eg, poorly controlled diabetes, Cushing syndrome, chronic renal failure [as evidenced by a creatinine clearance < 30 ml/min])
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
The University of Texas Health Science Center at Tyler
Tyler, United StatesOpen The University of Texas Health Science Center at Tyler in Google Maps